Named Bioactive Compounds · Compound
Capseicin (Capsaicinoid)
Strong Evidencecompound
Hermetica Superfood Encyclopedia
Capsaicin is a vanilloid compound from chili peppers that activates TRPV1 receptors to deplete substance P from nerve endings. This mechanism makes it particularly effective for treating neuropathic pain conditions.
Capsaicin is an alkaloid compound extracted from hot peppers (Capsicum annuum and related species), specifically from the fruit's placental tissue - the white membrane holding seeds. It is isolated through solvent extraction or supercritical CO₂ methods and belongs to the vanilloid chemical class that activates TRPV1 receptors.
Clinical evidence includes a landmark double-blind trial (n=143) demonstrating significant pain reduction in postherpetic neuralgia with 0.075% capsaicin cream, and a randomized trial (n=51) showing improved swallowing function with 10 μM oral capsaicin solution. A systematic review (PROSPERO-registered) identified limited evidence for postoperative pain, while trials have shown promise for chemotherapy-induced neuropathy (n=76) and diabetic neuropathy (n=40).
Topical cream: 0.075% applied to affected areas (studied for neuropathic pain). High-concentration patch: 8% formulation for localized pain. Oral solution: 10 μM (10 mL three times daily before meals) for dysphagia. Consult a healthcare provider before starting any new supplement.
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is the principal capsaicinoid found in Capsicum species (chili peppers). It is not a significant source of macronutrients, vitamins, or minerals itself, as it is typically consumed or applied in microgram-to-milligram quantities. Key details: • Chemical formula: C18H27NO3; molecular weight: 305.41 g/mol. • Concentration in source foods: Fresh hot peppers contain approximately 0.1–1.0% capsaicinoids by dry weight; habanero peppers can reach up to 2–3% capsaicinoids. Capsaicin typically represents 60–70% of total capsaicinoids, with dihydrocapsaicin comprising ~20–25%, and minor capsaicinoids (nordihydrocapsaicin, homodihydrocapsaicin, homocapsaicin) making up the remainder. • Scoville Heat Units (SHU): Pure capsaicin rates ~16,000,000 SHU; dietary intake from hot peppers typically delivers 0.5–5 mg capsaicin per gram of dried chili. • Bioactive co-compounds in whole pepper matrix: Vitamin C (approximately 140–240 mg per 100 g fresh pepper), provitamin A carotenoids (β-carotene, β-cryptoxanthin; up to 10,000–20,000 µg per 100 g in red varieties), vitamin E (tocopherols; ~0.7–2.0 mg per 100 g), vitamin K (~14 µg per 100 g), potassium (~320 mg per 100 g), dietary fiber (~1.5–2.0 g per 100 g fresh), and flavonoids (luteolin, quercetin). • Bioavailability: Oral capsaicin is rapidly absorbed in the stomach and upper intestinal tract with approximately 50–90% bioavailability depending on formulation and food matrix. Peak plasma concentration occurs within 45–60 minutes of oral ingestion. It is extensively metabolized hepatically via CYP450 enzymes (primarily CYP3A4 and CYP1A2) and vanilloid pathways. Half-life in plasma is approximately 24–26 minutes. Lipophilic nature (logP ~3.04) facilitates transdermal absorption, which is exploited in topical patches (e.g., 8% capsaicin patch delivers ~179 mg per 280 cm² patch). Topical bioavailability is low systemically (<1% reaches circulation) but achieves high local tissue concentrations. • Mechanism of action target: Transient receptor potential vanilloid 1 (TRPV1) channel agonist; prolonged exposure causes defunctionalization of nociceptive nerve fibers via reversible depletion of substance P and calcitonin gene-related peptide (CGRP). • Typical dietary intake: Estimated average daily capsaicin consumption ranges from 0.5–1.0 mg/day in Western diets to 25–200 mg/day in high-consumption regions (Mexico, India, Thailand, Korea). • Therapeutic doses studied: Topical creams 0.025–0.1% applied 3–4 times daily; high-concentration patches 8% (179 mg capsaicin) single application for 30–60 minutes; oral supplements 2–6 mg/day in capsule form.
Capsaicin binds to and activates TRPV1 (vanilloid receptor 1) channels on sensory neurons, causing initial excitation followed by desensitization. This process depletes substance P and CGRP from nerve terminals, reducing pain signal transmission. The receptor desensitization can last weeks to months, providing sustained analgesic effects.
Strong evidence from a randomized controlled trial (n=143) shows 86% of postherpetic neuralgia patients maintained pain relief over 2 years with capsaicin treatment. Moderate evidence from an RCT (n=76) demonstrates significantly lower neuropathy grades in chemotherapy-induced peripheral neuropathy compared to control. Additional studies suggest benefits for swallowing function in elderly patients, though this evidence is more limited. Most clinical applications focus on topical formulations for localized pain management.
Topical capsaicin commonly causes burning sensation, erythema, and skin irritation at application sites, typically diminishing with continued use. Systemic absorption is minimal with topical application, but oral capsaicin can cause gastric irritation and may interact with ACE inhibitors and anticoagulants. Contraindicated on broken or irritated skin and should be avoided during pregnancy and breastfeeding due to insufficient safety data. Patients should avoid contact with eyes and mucous membranes during application.
